| Identification | Back Directory | [Name]
MYX1715 | [CAS]
2445448-66-6 | [Synonyms]
MYX1715
4-(2-(2-(3-(2-aminoethyl)imidazo[1,2-a]pyridin-6-yl)-5-chlorophenoxy)ethyl)-N,N,1,5-tetramethyl-1H-pyrazole-3-carboxamide
1H-Pyrazole-3-carboxamide, 4-[2-[2-[3-(2-aminoethyl)imidazo[1,2-a]pyridin-6-yl]-5-chlorophenoxy]ethyl]-N,N,1,5-tetramethyl- | [Molecular Formula]
C25H29ClN6O2 | [MOL File]
2445448-66-6.mol | [Molecular Weight]
480.99 |
| Hazard Information | Back Directory | [Uses]
MYX1715 is an inhibitor of N-Myristoyltransferase (NMT) with a KD value of 0.09 nM. MYX1715 inhibits the proliferation of LU0884 and LU2511 with IC50 values of 44 nM and 9 nM. MYX1715 exhibits antitumor efficacy against neuroblastoma and gastric cancer in mouse models. MYX1715 can be used as ADC toxin[1][2]. | [in vivo]
MYX1715 (12.5 and 25 mg/kg, a single dose for 20 days) prevents tumour growth in a Th-MYCN GEMM model, in a DLBCL xenograft model and in a gastric cancer xenograft model[1].
| Animal Model: | Th-MYCN GEMM mice model, DLBCL xenograft mice model and gastric cancer xenograft mice model[1] | | Dosage: | 12.5 and 25 mg/kg | | Administration: | a single dose for 20 days | | Result: | Inhibited tumour growth in mice bearing tumors. |
| [References]
[1] Zhang J, et al. Dysregulation of MYC-Family Proteins Sensitises Cancers to NMT Inhibition: Identification of NMTi Sensitivity and Mechanism[J]. Cancer Research, 2023, 83(7_Supplement): 4871-4871.
[2] Carr R, et al. N-Myristoyltransferase (NMT) inhibitors are completely novel payloads for Antibody Drug Conjugates that deliver extensive tumor regression at well tolerated doses[J]. |
|
| Company Name: |
Abosyn
|
| Tel: |
0512-69561983 13914027025 |
| Website: |
abosyn.cn/ |
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
|